Table 1 Effects of the Polypill on the risks of ischaemic heart disease (IHD) and
stroke after two years of treatment at age 55-64
|
|
|
|
% reduction in risk (95%
CI)*
|
|
Risk factor
|
Agent
|
Reduction in risk factor
|
IHD event
|
Stroke
|
Source of evidence
|
LDL cholesterol
|
Statin
|
1.8 mmol/l (70 mg/dl) reduction in LDL cholesterol
|
61 (51 to 71)
|
17 (9 to 25)
|
Law et al1
|
Blood pressure
|
Three classes of drug at half standard dose
|
11 mm Hg diastolic
|
46 (39 to 53)
|
63 (55 to 70)
|
Law et al16
|
Serum homocysteine
|
Folic acid (0.8 mg/day)
|
3 µmol/l
|
16 (11 to 20)
|
24 (15 to 33)
|
Wald et al9
|
Platelet function
|
Aspirin (75 mg/day)
|
Not quantified
|
32 (23 to 40)
|
16 (7 to 25)
|
Table A on bmj.com
|
Combined effect
|
All
|
|
88 (84 to 91)
|
80 (71 to 87)
|
|
|
LDL=low density lipoprotein.
* 95% confidence intervals include imprecision of the estimates of both the
agent reducing the risk factor and the risk factor reduction decreasing
risk.
Atorvastatin 10 mg/day, or simvastatin or lovastatin 40 mg/day taken in the
evening or 80 mg/day taken in the morning.